JHJan Heering

Jan Heering

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Heering has a total of 239 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure Merging Approach Leads to New Dual Potent and Selective USP25/USP28 Inhibitors

    by Victor Hernandez-Olmos, Jonathan Vincent Patzke, Caroline E. Stone, Radhika Karal Nair, Kathrin Weller, Florian Sauer, Erik Endres, Oumaima Jamai, Lea Rachor, Cornelia H. Warmutz, et al.

    USP25 and USP28 are critical deubiquitylases (DUBs) that have been implicated in various diseases, particularly cancer and cardiac dysfunction. Several small-molecule inhibitors have been reported, exhibiting dual inhibitory activity in the low micromolar range. In this study, we present a strategy that merges structural features of the previously identified inhibitors AZ1 and vismodegib to develop a new class of potent dual inhibitors. Several of these newly synthesized compounds exhibit high potency across multiple orthogonal assays and demonstrate excellent selectivity over other ubiquitin-specific proteases. Moreover, a suitable negative control has also been identified, supporting the validity of the observed effects in cellular assays. These results highlight the potential of these compounds to serve as advanced chemical probes for dual USP25/USP28 inhibition and as candidates for further therapeutic development.


  • Open Access

    Optimization and Evaluation of Complementary Degrader Discovery Assays for Application in Screening

    by Johanna Huchting, Arjen Weller, Moyra Schweizer, Mona Brandt, Jan Heering, Maria Kuzikov, Markus Wolf, Jeanette Reinshagen, Markus A. Queisser, Philip Gribbon, et al.

    Targeted protein degradation (TPD) mediated by molecular glues is an innovative pharmaceutical paradigm. By binding to and modulating the surface of an E3-ligase component, molecular glue degraders can facilitate the recruitment of a specific target protein (or vice versa) and ultimately invoke target degradation. This mode of action results in specific challenges for the development of rational discovery strategies, and complex hit validation workflows may be required to reliably eliminate compounds that elicit nonspecific effects. With the aim to guide screening efforts, we optimized two orthogonal cell-based, target-centric assays for degrader discovery: (1) a time-resolved FRET assay directly quantifying the levels of a target protein and its degradation (signal inhibition) and (2) an assay coupling TPD to cell growth (signal rescue). To enable a deeper understanding of the individual assays' strengths and limitations, we compared their statistical performance as well as respective hit populations by screening a specifically designed collection of about 1000 compounds containing well-annotated reference compounds and known frequent hitters (FHs). We found that the signal rescue format reliably and specifically captured active target degraders while efficiently filtering out interfering or FH compounds. Importantly, this format achieved to retrieve lower potency hits, which might be desirable in order to confidently include as many diverse chemical starting points as possible at the start of a drug discovery project.


  • Open Access

    Structure-Based Design of PROTACS for the Degradation of Soluble Epoxide Hydrolase

    by Julia Schönfeld, Steffen Brunst, Ludmila Ciomirtan, Lena Willmer, Michel A. Chromik, Adarsh Kumar, Timo Froemel, Nick Liebisch, Arne Hackspacher, Johanna H. M. Ehrler, et al.

    The bifunctional soluble epoxide hydrolase (sEH) represents a promising target for inflammation-related diseases. Although potent inhibitors targeting each domain are available, sEH-PROTACs offer the unique ability to simultaneously block both enzymatic functions, mimicking the sEH knockout phenotype, which has been associated with reducing inflammation, including neuroinflammation, and delaying the progression of Alzheimer's disease. Herein, we report the structure-based development of a potent sEH-PROTAC as a useful pharmacological tool. In order to facilitate a rapid testing of the PROTACs, a cell-based sEH degradation assay was developed utilizing HiBiT technology. We designed and synthesized 24 PROTACs. Furthermore, cocrystallization of sEH with two selected PROTACs allowed us to explore the binding mode and rationalize the most optimal linker length. After comprehensive biological and physicochemical characterization of this series, the most optimal PROTAC 23 was identified in primary human and murine cells, highlighting the potential of using 23 in disease-relevant cell and tissue models.


  • A First-in-Class Hepatocyte Nuclear Factor 4 Agonist

    by Espen Schallmayer, Vasily Morozov, Silke Duensing-Kropp, Lasse Schallmayer, Leann Schüffner, Manfred Schubert-Zsilavecz, Jörg Pabel, Georg Höfner, Jan Heering, Julian A. Marschner, et al.

    Hepatocyte nuclear factor 4 (HNF4) is an orphan nuclear receptor implicated, for example, in pancreatic islet gene expression and hepatic regulation of glucose and lipid metabolism. Mutations in the HNF4α gene are responsible for the inheritable maturity-onset diabetes of the young 1 (MODY-1), supporting the therapeutic potential of HNF4 activation in metabolic diseases. However, exploration and validation of HNF4 as a therapeutic target is hindered by the lack of suitable ligands. Here, we report the development of the first high-affinity HNF4 agonists by extension of a fragment screening hit and systematic SAR elucidation. Structural modification allowed tuning of the chemotype for both HNF4 agonism and inverse agonism. X-ray structure analysis demonstrated orthosteric site occupation by the new ligand scaffold mimicking the natural fatty acid ligand binding. The most active descendant displayed low nanomolar HNF4 agonist potency and binding affinity and favorable selectivity, enabling unprecedented studies on HNF4 biology as a chemical tool.


  • Fragment-Based Discovery of Drug-like LRH-1 Agonists

    by Alisa Lang, Niklas Ildefeld, Felix F. Lillich, Astrid Kaiser, Romy Busch, Julian A. Marschner, Ewgenij Proschak, Jan Heering, Manfred Schubert-Zsilavecz, Daniel Merk

    The phospholipid sensing transcription factor liver receptor homologue 1 (LRH-1) participates in the transcriptional regulation of metabolic balance and inflammation in liver, pancreas, and other tissues. It is an emerging target for metabolic dysfunction, fatty liver disease, and cancer, but LRH-1 modulators are rare and lack drug-like properties. We discovered new LRH-1 ligands with improved physicochemical features in a fragment-based approach and optimized a venlafaxine-related lead for LRH-1 activation. Despite a strict structure-activity relationship, systematic structural variation resulted in a new LRH-1 agonist scaffold with strong activation efficacy, validated direct and cellular target engagement, and anti-inflammatory and ER-stress-resolving properties in functional cellular settings.


  • Fatty Acid Mimetic Fragments as Liver Receptor Homologue-1 Modulators

    by Alisa Lang, Tanja Stiller, Niklas Ildefeld, Pascal Heitel, Laura Isigkeit, Ewgenij Proschak, Jan Heering, Manfred Schubert-Zsilavecz, Daniel Merk

    The phospholipid-sensing transcription factor liver receptor homologue-1 (LRH-1) is mainly found in the liver, intestine, and pancreas where it participates in the transcriptional regulation of genes involved in cholesterol and glucose metabolism, inflammation, and endoplasmic reticulum stress. It holds promise as a target in metabolic disease and hepatic/intestinal inflammation treatment, and preliminary evidence suggests potential of LRH-1 modulation for contraception, but LRH-1 modulators are very rare. Based on phospholipid binding to LRH-1, we hypothesized potential for fatty acid mimetics as LRH-1 modulators and discovered new ligand chemotypes by focused fragment screening. Preliminary SAR elucidation, orthogonal activity validation, and target engagement studies highlighted two fragment-like leads for LRH-1 agonist development.


  • Open Access

    Orphan G protein-coupled receptor GPRC5B controls macrophage function by facilitating prostaglandin E receptor 2 signaling

    by Jeonghyeon Kwon, Haruya Kawase, Kenny Mattonet, Stefan Guenther, Lisa Hahnefeld, Jamal Shamsara, Jan Heering, Michael Kurz, Sina Kirchhofer, Cornelius Krasel, et al.

    Macrophages express numerous G protein-coupled receptors (GPCRs) that regulate adhesion, migration, and activation, but the function of orphan receptor GPRC5B in macrophages is unknown. Both resident peritoneal and bone marrow-derived macrophages from myeloid-specific GPRC5B-deficient mice show increased migration and phagocytosis, resulting in improved bacterial clearance in a peritonitis model. In other models such as myocardial infarction, increased myeloid cell recruitment has adverse effects. Mechanistically, we found that GPRC5B physically interacts with GPCRs of the prostanoid receptor family, resulting in enhanced signaling through the prostaglandin E receptor 2 (EP2). In GPRC5B-deficient macrophages, EP2-mediated anti-inflammatory effects are diminished, resulting in hyperactivity. Using in silico modelling and docking, we identify residues potentially mediating GPRC5B/EP2 dimerization and show that their mutation results in loss of GPRC5B-mediated facilitation of EP2 signaling. Finally, we demonstrate that decoy peptides mimicking the interacting sequence are able to reduce GPRC5B-mediated facilitation of EP2-induced cAMP signaling in macrophages.


  • Open Access

    Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets

    by Martin P. Schwalm, Johannes Dopfer, Adarsh Kumar, Francesco A. Greco, Nicolas Bauer, Frank Löhr, Jan Heering, Sara Cano-Franco, Severin Lechner, Thomas Hanke, et al.

    Recent successes in developing small molecule degraders that act through the ubiquitin system have spurred efforts to extend this technology to other mechanisms, including the autophagosomal-lysosomal pathway. Therefore, reports of autophagosome tethering compounds (ATTECs) have received considerable attention from the drug development community. ATTECs are based on the recruitment of targets to LC3/GABARAP, a family of ubiquitin-like proteins that presumably bind to the autophagosome membrane and tether cargo-loaded autophagy receptors into the autophagosome. In this work, we rigorously tested the target engagement of the reported ATTECs to validate the existing LC3/GABARAP ligands. Surprisingly, we were unable to detect interaction with their designated target LC3 using a diversity of biophysical methods. Intrigued by the idea of developing ATTECs, we evaluated the ligandability of LC3/GABARAP by in silico docking and large-scale crystallographic fragment screening. Data based on approximately 1000 crystal structures revealed that most fragments bound to the HP2 but not to the HP1 pocket within the LIR docking site, suggesting a favorable ligandability of HP2. Through this study, we identified diverse validated LC3/GABARAP ligands and fragments as starting points for chemical probe and ATTEC development.


  • Tuning RXR Modulators for PGC1α Recruitment

    by Felix Nawa, Minh Sai, Jan Vietor, Roman Schwarzenbach, Anesa Bitić, Sina Wolff, Niklas Ildefeld, Jörg Pabel, Thomas Wein, Julian A. Marschner, et al.

    The molecular activation mechanism of the nuclear retinoid X receptors (RXRs) crucially involves ligand-induced corepressor release and coactivator recruitment which mediate transcriptional repression or activation. The ability of RXR to bind diverse coactivators suggests that a coregulator-selective modulation by ligands may open an avenue to tissue- or gene-selective RXR activation. Here, we identified strong induction of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1 alpha) binding to RXR by a synthetic agonist but not by the endogenous ligand 9-cis retinoic acid. Structure-guided diversification of this lead resulted in a set of three structurally related RXR agonists with different ability to promote PGC1 alpha recruitment in cell-free and cellular context. These results demonstrate that selective modulation of coregulator recruitment to RXR can be achieved with molecular glues and potentially open new therapeutic opportunities by targeting the ligand-induced RXR-PGC1 alpha interaction.


  • Open Access

    HTRF-based assay for detection of mono-ADP-ribosyl hydrolyzing macrodomains and inhibitor screening

    by Niklas Ildefeld, Dieter Steinhilber, Ewgenij Proschak, Jan Heering